The research library
Every primary source behind a claim on this site, tier-graded for provenance and tagged for the strength of the evidence it carries. 17 of 36 sources match the filters.
- Sources indexed
- 36
- Peptides covered
- 20
- Tier 1 share
- 100%
F·Filter
Reset all- Tier 1 · Peer primarystrongRCT
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frías JP, et al. · 2023 · New England Journal of Medicine
- Tier 1 · Peer primarystrongRCT
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. · 2023 · New England Journal of Medicine
- Tier 1 · Peer primarystrongRCT
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial
Karaa A, Bertini E, Carelli V, et al. · 2023 · Neurology
- Tier 1 · Peer primarystrongRCT
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, et al. · 2022 · New England Journal of Medicine
- Tier 1 · Peer primarystrongRCT
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
Wilding JPH, Batterham RL, Davies M, et al. · 2022 · Diabetes, Obesity and Metabolism
- Tier 1 · Peer primarystrongRCT
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial
Rubino D, Abrahamsson N, Davies M, et al. · 2021 · JAMA
- Tier 1 · Peer primarystrongRCT
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH, Batterham RL, Calanna S, et al. · 2021 · New England Journal of Medicine
- Tier 1 · Peer primarystrongRCT
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías JP, Davies MJ, Rosenstock J, et al. · 2021 · New England Journal of Medicine
- Tier 1 · Peer primarystrongRCT
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Kingsberg SA, Clayton AH, Portman D, et al. · 2019 · Obstetrics and Gynecology
- Tier 1 · Peer primarystrongRCT
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso SP, Bain SC, Consoli A, et al. · 2016 · New England Journal of Medicine
- Tier 1 · Peer primarystrongMechanistic
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance
Lee C, Zeng J, Drew BG, et al. · 2015 · Cell Metabolism
- Tier 1 · Peer primarystrongMechanistic
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
Lau J, Bloch P, Schäffer L, et al. · 2015 · Journal of Medicinal Chemistry
- Tier 1 · Peer primarystrongMeta-analysis
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
Falutz J, Mamputu JC, Potvin D, et al. · 2010 · Journal of Clinical Endocrinology & Metabolism
- Tier 1 · Peer primarystrongRCT
Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial
Nass R, Pezzoli SS, Oliveri MC, et al. · 2008 · Annals of Internal Medicine
- Tier 1 · Peer primarystrongRCT
Metabolic effects of a growth hormone-releasing factor in patients with HIV
Falutz J, Allas S, Blot K, et al. · 2007 · New England Journal of Medicine
- Tier 1 · Peer primarystrongRCT
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman SL, Neale A, Lawrence B, et al. · 2006 · Journal of Clinical Endocrinology & Metabolism
- Tier 1 · Peer primarystrongMechanistic
Ipamorelin, the first selective growth hormone secretagogue
Raun K, Hansen BS, Johansen NL, et al. · 1998 · European Journal of Endocrinology